2014 is the year of biological medicine industry vigorously sideways, the overall when shi Yang, heat continuously but no boiling point, most companies are facing transformation, especially the foreign mergers and acquisitions, the layout of the domestic listed companies are brings to the industry is not the same watch for: 
1. The countries in transition 
863973 as the government's most important competitive qualification will be cancelled, countries will naturally be lift dimensions. From related news, the government will set up the enterprise management to fund, open scientific research type chong hing enterprise's application for funding. Have not yet from the company level change decision making in the future will undoubtedly encounter huge winter. 
2. ThermoFisher m&a Life after Chinese layout 
Historically, the ABI Invitrogen acquisition in June 2008, the integration of the Chinese market for three years. This has brought very much user confusion, which was also show strong channels provide a lot of power. Now this merger integration might seem more quickly, investigate its reason, we would like to understand more for information access through for capital layout integration provides a good display space. 
3. The new thought of new three board bring industry enterprises 
New three board will undoubtedly bring to industry enterprises drugs sort of excitement, a lot of companies listed, such as the proud creatures, gemma gene and so on, more and more national enterprises begin to log in to the capital stage, the 20 years (the government) to have a meal of one relies on industry, is also a mixed message, under the pressure of capital city, is it to be or not to be, this is a problem, not a few years we would like to see a higher dimension of the company, but later will no doubt have more bodies. 
4. The source in union purchase beike 13% stake 
Before the end of this message we are top to this position, because of its strong degree, and infinite imaginary space to industry. Take a look at two companies. Source in the Concorde [600645] as the a-share listed companies, shares all the way walk to 40 yuan, the umbilical cord blood to save the business has been surrounded by all kinds of sound, but aside from technology, as A commercial entity. The business model is a success, especially for China's one child policy needs into is beautiful. It also gave many so-called business unit in China a wake, creation of technology products that must be in line with market demand, don't say you how good technology, people fail to recognize the approval, this, is very important. Look at beike, situated at the magic of shenzhen enterprises, has been the strong focus of the journal Science, now still didn't give up in the field of stem cell, used for forward. We should give companies like applause, no matter how the future, their efforts are now quietly move this huge industry. In 2015, stem cell is the keyword for China. 
5. "after" Illumina sequencing market 
It is said to Illumina market share, is a joke, this and focus on research and development company who perform its handheld device maker e-ten out already and gradually the proud attitude. This model can't reminded me of the pharmaceutical industry, high research and development, the high monopoly, high-yield model will go into our industry. , of course, the first table, we first need to quiet a quiet, in sequencing market, purple xin pharmaceutical co., Ann gene, shenzhen China mostly looking for layout, but the huge gold undoubtedly keep out the line of sight of people. The whole industrial chain huge nuggets source not only so, sample preparation of market demand, Eppendorf this progress to solve the company known as titration, explosive in the shown remarkable in this area. And then the data processing companies, such as berry and kang has made good achievements, there are countless small companies such as Shanghai its Ming also in talent, we might as well see earn more and see what the Denver nuggets, or selling shovels basin. 
6. "little fresh meat" products of war 
A market can never rely on some live for 5 years or above level product with a grandpa, in those years we see little fresh meat are beefing up in the industry, the future belongs to them, this no doubt. Digital PCR, individualized flow cytometry instrument and so on, of course, each of the PK survive completion is the king in the future. 
7. Paper after the second world we are faced with the embarrassing situation 
When China paper quantity after entering into the world's second, may in the future for a long time in the position to do a quiet beautiful. So don't have a clear growth situation, the government is unlikely to be in this respect have too much patience. So how to improve the quality of paper, how to improve the conversion (rather than just stop in paper level), bound to new g-spot is industry. Bring the whole medical biological industry adjustment and opportunities would be huge. Which technology services company, translational medicine products, capital docking will be the biggest beneficiaries of foreseeable. 
8. Debris solution thinking time 
From the earliest biological equipment, to the valley of biological, clove garden for thinking about the Internet (in fact this is the prototype of fragments of time, to the large number of enterprises to discuss, and even the present academic content, activity marketing, "Internet thinking" mentioned many times 2014 years. Then, from the point of practical effect, biological medicine industry in the "Internet thinking" is mainly adopted in the marketing level, although the pioneers obtain very good effect, but can excavate space is very large. The micro letter was born brought countless enterprise SAP reform more urgent. How to quickly adapt to the marketing changes, the market deal with fragments of time, is every company need to pay attention to the market. Here again, I'm afraid, it is not the end of the rising cost of such a simple in the future. 
9. The antibody reagents enterprise model change 
Once upon a time, the custom is how the word. But also brings countless companies nightmare. The uniqueness of the product brings to the biological products quality control problem. Small companies such as the spring breeze, then several years of growth bottlenecks, to break through the bottleneck and by the quality support dead cases abound. Self production mode is gradually replaced by the quality control of purchasing trend, the question is, who is to make standard. We have to wait and see. 
10. Channel changes 
2014 is channel shuffle of the company, the traditional proxy pattern in 2014 received a huge challenge. Life network marketing platform, Sigma into Merck, these channels are thinking transformation. How to change, adapt to the market to take off again, is also many channels for companies to consider problem. Both upstream and downstream in thinking, have serious problems, such a game will inevitably intensify in 2015. For 200000 industry sales professionals, to worry about, needs to change.